Why glioma trial monitoring matters
Glioma encompasses a broad spectrum of primary brain tumors — from grade 2 IDH-mutant astrocytomas with median survival measured in decades, to grade 4 glioblastoma (GBM) with median survival under 15 months. Much of the public and commercial attention in neuro-oncology goes to glioblastoma, but the broader glioma landscape is equally important for pharma strategy teams: the WHO 2021 CNS tumor reclassification, which now defines glioma subtypes by molecular markers (IDH mutation, 1p/19q codeletion, CDKN2A/B homozygous deletion) rather than histology alone, has fundamentally reshaped how trials are designed and how regulatory submissions are structured.
IDH-mutant gliomas (grades 2 and 3 astrocytoma, oligodendroglioma) represent a distinct and commercially significant opportunity. These tumors are slower-growing than GBM, affect a younger patient population (often diagnosed in the 30s and 40s), and have a well-characterized driver mutation amenable to targeted therapy. The approval of vorasidenib (Servier/Agios) for IDH-mutant grade 2 glioma in 2024 marked the first molecularly targeted therapy approved specifically for low-grade glioma — and opened a new chapter for combination trials, next-generation IDH inhibitors, and IDH-adjacent targets.
Key signals that professionals track:
- New trials testing IDH1/IDH2 inhibitors (ivosidenib, enasidenib, vorasidenib) in grade 2–3 glioma, either as monotherapy or in combination with temozolomide or radiotherapy
- MGMT promoter methylation-stratified trials — a critical biomarker that predicts benefit from temozolomide and is used to stratify or enrich enrollment in most GBM and high-grade glioma trials
- CAR-T and CAR-NK cell therapy trials targeting GBM-associated antigens (EGFRvIII, IL13Ra2, GD2, B7-H3) — Phase 1 CNS delivery trials enrolling in academic centers
- Trials testing novel delivery mechanisms for CNS drug penetration — convection-enhanced delivery (CED), blood-brain barrier opening with focused ultrasound, and intratumoral injection platforms
- Bevacizumab combination and sequencing trials in recurrent glioma, where the agent is widely used off-label despite limited Phase 3 survival benefit
Get daily glioma trial digest
Set your profile once. Receive a clean digest every morning with new trials and updates matching your criteria.
Start Free — No Credit CardWhat DataLookout monitors for glioma
DataLookout pulls directly from the ClinicalTrials.gov API every day. For a glioma watch profile, you can configure:
- Condition keywords: "glioma", "IDH mutant glioma", "low-grade glioma", "diffuse glioma", "astrocytoma", "oligodendroglioma", "grade 2 glioma", "grade 3 glioma"
- Phase filter: Phase 1 only, Phase 2/3, or all phases
- Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
- Status filter: Recruiting only, all active studies, or any status
The glioma pipeline landscape in 2026
The glioma pipeline in 2026 is being shaped by two converging forces: the WHO 2021 molecular reclassification of CNS tumors and the arrival of the first targeted agent for IDH-mutant disease (vorasidenib, approved 2024). The active Phase 3 glioma trial count (live on this page) is historically high, reflecting genuine clinical momentum after two decades of failed GBM trials.
Active Phase 3 programs (selected)
| NCT ID | Trial | Sponsor | Status |
|---|---|---|---|
| NCT06780930 | Vorasidenib in Asian participants with residual IDH-mutant glioma | Servier | Active |
| NCT06556563 | EF-41/KEYNOTE-D58: Optune + TMZ + Pembrolizumab for newly diagnosed GBM | NovoCure / Merck | Recruiting |
| NCT05095376 | Adding lomustine to standard-of-care TMZ in newly diagnosed GBM (MGMT methylated) | NRG Oncology | Active |
| NCT06388733 | Niraparib vs. TMZ in newly diagnosed MGMT-unmethylated GBM (Ivy Brain Tumor Center) | Ivy Brain Tumor Center | Active, Not Recruiting |
| NCT05303519 | SIGMA: Safusidenib (IDH1 inhibitor) maintenance in IDH1-mutant glioma | Nuvation Bio | Recruiting |
| NCT07100730 | TLX101-Tx (targeted alpha therapy) + SoC vs. SoC alone in GBM | Telix Pharmaceuticals | Recruiting |
IDH-mutant glioma: the targeted therapy era begins
Vorasidenib (Servier/Agios) was approved by the FDA in August 2024 for non-enhancing IDH-mutant grade 2 glioma — the first molecularly targeted therapy for low-grade CNS tumors. The INDIGO trial demonstrated a 61% reduction in risk of disease progression versus placebo. The next wave of trials tests whether vorasidenib can be combined with radiotherapy, temozolomide, or immune checkpoint blockade to achieve deeper and more durable responses in IDH-mutant grade 2 and 3 gliomas.
A second IDH inhibitor — safusidenib (Nuvation Bio, NCT05303519, Phase 3/SIGMA trial) — is now recruiting for IDH1-mutant glioma maintenance therapy, positioning as a potential competitor to vorasidenib with a differentiated binding profile. Teams tracking the IDH-mutant glioma space need to follow both programs simultaneously.
GBM: no breakthrough yet, but 3 key active Phase 3 programs
For grade 4 glioblastoma and IDH-wildtype high-grade glioma, the standard of care (temozolomide + radiotherapy, Stupp protocol) has not meaningfully improved in 20 years despite hundreds of Phase 2 trials. MGMT promoter methylation status remains the primary predictive biomarker — patients with MGMT-methylated GBM respond to temozolomide and are the target of most alkylating agent intensification trials, while MGMT-unmethylated patients are the population most in need of new approaches (hence the niraparib PARP inhibitor trial, NCT06388733).
The TTFields + immunotherapy combination (EF-41/KEYNOTE-D58, NCT06556563) is one of the highest-profile active GBM Phase 3 trials, combining Optune (NovoCure's tumor treating fields device) with pembrolizumab and TMZ in the post-chemoradiation setting for newly diagnosed GBM. NovoCure's earlier EF-14 trial showed a survival advantage for TTFields alone; this trial tests whether adding PD-1 blockade deepens the benefit.
Biomarker landscape: what drives trial stratification
Molecular markers now determine which glioma trials a patient is eligible for:
- IDH1/IDH2 mutation: Required for vorasidenib, safusidenib, ivosidenib, and enasidenib trials. IDH-mutant = grade 2/3 astrocytoma, oligodendroglioma, IDH-mutant grade 4 astrocytoma. IDH-wildtype = GBM (most cases).
- MGMT methylation: Stratification variable in virtually all GBM trials. Methylated = benefits from TMZ; unmethylated patients are recruited into MGMT-independent approaches (immunotherapy, PARP inhibitors).
- 1p/19q codeletion: Defines oligodendroglioma (IDH-mutant + 1p/19q codeletion) — a specific subtype with different natural history, response to PCV chemotherapy, and trial eligibility.
- EGFR amplification / EGFRvIII: Present in ~30–50% of GBM; targeted CAR-T (EGFRvIII-directed) and small molecule approaches in Phase 1/2.
- TERT promoter mutation: Present in most IDH-wildtype GBM, used for diagnostic confirmation but not yet a direct drug target.
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Glioma trial on your watchlist. Each change is classified as critical, notable, or minor, so a completion date pushed out by two years does not read the same as a contact-details edit.
Who uses glioma trial monitoring
Neuro-oncology pharma and biotech competitive intelligence teams
Companies developing assets for glioma — whether IDH inhibitors, immunotherapy combinations, novel CNS delivery platforms, or radiation sensitizers — need continuous visibility into competitor trial activity. The glioma landscape is fragmented across multiple grades and molecular subtypes, meaning a single company may need to simultaneously track grade 2 IDH-mutant astrocytoma trials, grade 4 GBM trials, and pediatric glioma trials (DIPG/DMG) with distinct molecular profiles. DataLookout allows CI teams to configure separate watch profiles for each subtype and receive one organized daily digest without manual ClinicalTrials.gov searches.
BD teams evaluating CNS oncology assets
Glioma is an active area for business development, both because the unmet need is severe and because the molecularly defined subtypes (IDH mutant, EGFR amplified, MGMT methylated) create opportunities for precision oncology licensing deals. BD teams looking to in-license early-stage CNS assets use DataLookout to identify Phase 1/2 trials generating early signals in IDH-mutant or recurrent GBM populations — often the first public data point before any publication or conference abstract. Monitoring trial openings and status changes is a way to get into conversations with academic and biotech sponsors before a broader deal process begins.
Academic neuro-oncology research and clinical operations teams
Major academic medical centers running investigator-initiated glioma trials — testing novel surgical adjuncts, radiation techniques, immunotherapy combinations, or metabolic interventions — use DataLookout to track the competitive landscape for grant applications and protocol design. Knowing what is actively enrolling in recurrent IDH-mutant glioma avoids designing a duplicative trial, helps identify potential industry co-sponsorship opportunities, and provides the literature context required for IRB submissions and NIH grant applications.
Frequently asked questions
How current is the glioma trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.
Can I track glioma separately from glioblastoma (GBM)?
Yes. You can set up separate watch profiles — one using keywords like "glioma", "IDH mutant", "astrocytoma", "oligodendroglioma" to track lower-grade and IDH-mutant disease, and a separate profile using "glioblastoma" or "GBM" for grade 4 IDH-wildtype disease. The two populations enroll in largely distinct trials, so separating them reduces noise and makes your daily digest more actionable. The Starter plan supports up to 5 simultaneous watch profiles, which is well-suited for teams tracking multiple CNS tumor types.
Does DataLookout cover international trials?
ClinicalTrials.gov includes trials conducted internationally, so yes — international trials registered on ClinicalTrials.gov are included. This covers most major industry-sponsored programs worldwide.
549 active trials, 323 recruiting.
Industry sponsors run 84 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 69.
| Top industry sponsor | Active trials |
|---|---|
| Nuvation Bio | 3 |
| Pfizer | 3 |
| Beijing Bio-Targeting Therapeutics Technology Co., Ltd | 2 |
| Beijing Biotech | 2 |
| Day One Biopharmaceuticals, Inc. | 2 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS… NCT04870944 | Recruiting | Recruitment resumed after suspension | 2026-09-12 |
| A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With… NCT06357377 | Recruiting | Completion pushed: 2026-10 → 2027-07 | 2026-09-16 |
| A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With… NCT04201457 | Active, Not Recruiting | Completion pushed: 2026-03-31 → 2026-12-31 | 2026-09-12 |
| Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re)… NCT07061626 | Recruiting | Completion pushed: 2027-03 → 2028-03 | 2026-09-10 |
| Glioma Developmental and HyperActive Ras Tumor (DHART) Board NCT05489783 | Recruiting | Completion pushed: 2026-07-31 → 2027-07-31 | 2026-09-01 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.